Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET
Company Representatives
George Lasezkay - Chief Executive Officer
Tom Ciulla - Chief Medical Officer, Chief Development Officer
Charles Deignan - Chief Financial Officer
Dr. Arshad Khanani - Managing Partner at Sierra Eye Associates, Clinical Associate Professor at the University of Nevada
Jenny Kobin - Investor Relations
Conference Call Participants
Andreas Argyrides - Wedbush
Annabel Samimy - Stifel
John Wolleben - JMP Securities
Yi Chen - H.C. Wainwright
Serge Belanger - Needham & Company
Mayank Mamtani - B. Riley
Operator
Good morning, ladies and gentlemen, and welcome to the Clearside Biomedical Incorporated, Third Quarter 2022 Earnings Call. At this time all participants have been placed on a listen-only mode and the floor will be opened for questions and comments after the presentation.
It is now my pleasure to turn the floor over to your host, Jenny Kobin, with Investor Relations. Ma’am the floor is yours.
Jenny Kobin
Good morning and thank you for joining us on the call this morning. On today’s call we will have a brief discussion around Clearside’s third quarter financials, followed by the results from the OASIS Phase 1/2a clinical Trial.
Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we may make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2021 and our other SEC filings available on our website.
In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
On today's call we have George Lasezkay, our Chief Executive Officer; Dr. Thomas Ciulla, our Chief Medical Officer and Chief Development Officer; Charles Deignan, our Chief Financial Officer and Dr. Arshad Khanani, who is our Managing Partner at Sierra Eye Associates and a Clinical Associate Professor at the University of Nevada, Reno.